Transcat Expands into Latin America with Acquisition of SCM Metrology and Laboratories S.A.

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of test measurement, control and calibration, today announced the acquisition of SCM Metrology and Laboratories S.A. (“SCM”), a privately-held calibration services provider based in Costa Rica. The transaction closed effective April 9, 2026.

The acquisition price of approximately $13 million was paid in cash and is subject to customary adjustments and holdback provisions.

This acquisition establishes Transcat’s first operational presence in Latin America and advances the Company’s strategy to grow alongside customers in high-growth, highly regulated markets. It strengthens Transcat’s support for its multinational customer base by adding a broader local service footprint and creating opportunities for additional distribution sales tied to those service relationships.

Operating for more than 20 years, SCM has built strong relationships with multinational medical device and life sciences companies, many of which are already strategic customers or prospects of Transcat.

“The acquisition of SCM represents an important milestone for Transcat as we expand our services and expertise into the Latin American market,” said Jaime Irick, President and Chief Executive Officer of Transcat.

Irick continued, “We are excited to partner with SCM’s talented team and to support their growth with Transcat’s industry leading scale, resources, and proven calibration operating model.

SCM is an ISO/IEC 17025-accredited calibration laboratory located in the Coyol Free Trade Zone, Costa Rica’s premier medical device manufacturing and export hub. Costa Rica’s Free Trade Zones have attracted substantial foreign direct investment through long-standing government incentives and continue to expand through ongoing development and capacity additions.”

Management will discuss the transaction in more detail during Transcat’s Fourth Quarter Fiscal Year 2026 Earnings Conference Call.

ABOUT SCM METROLOGY AND LABORATORIES S.A.

SCM Metrology and Laboratories S.A. (“SCM”) is an ECA-accredited Calibration Laboratory according to ISO/IEC 17025. SCM provides solutions in the areas of metrology, metrological assurance, testing and inspection, through calibration services for measuring instruments, sale of measuring equipment, consulting and training in metrology and quality systems. With over 20 years in the market and a portfolio of more than 550 clients, SCM Metrology and Laboratories is the pioneering laboratory in the field of calibration accreditation and currently has the largest scope of accreditations in Central America. More information about SCM can be found at: SCMMetrologia.com.

ABOUT TRANSCAT

Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, Ireland, and Costa Rica. In addition, Transcat operates calibration labs in imbedded customer-site locations. The breadth and depth of measurement parameters addressed by Transcat’s ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry.

Transcat also operates as a leading value-added distributor that markets, sells and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity create a unique and compelling value proposition for its customers.

Transcat’s strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, Cost, Control and Optimizations services, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at: Transcat.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact and thus are subject to risks, uncertainties, and assumptions. Forward-looking statements relate to expectations, estimates, beliefs, assumptions, and predictions of future events and are identified by words such as “anticipate,” “believe,” “continue,” ”drive” “estimate,” “expect,” “look forward,” “opportunity,” “strategy,” “target,” “will,” “would,” and other similar words. All statements addressing operating performance, events or developments that Transcat expects or anticipates will occur in the future, including but not limited to statements relating to the successful integration of this acquisition, anticipated financial results, market position and geographic reach, customer preferences, outlook and changes in market conditions in the industries in which Transcat operates are forward-looking statements. Forward-looking statements should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties include those more fully described under the heading “Risk Factors” in Transcat’s reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 29, 2025. Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company disclaims any obligation to update, correct or publicly announce any revisions to any of the forward-looking statements contained in this news release, whether as the result of new information, future events or otherwise.